

Special Issue

Pathogen-Host Interactions: Implications for Vaccine Design

Message from the Guest Editor

How can studies on host-pathogen interactions influence the development of vaccines? What are the implications of the coevolution of a pathogen with its host for vaccine development? The outcome of the interaction of the host with a pathogen dictates the clinical severity of disease resulting from infection by that pathogen. This same basic principle also applies to the development of vaccines based on live, attenuated versions of a pathogen. Recent advances in cell culture systems, including 3D cultures and organoids, and animal models, are instrumental in gaining insight into pathogenesis and host immune response to infection by a pathogen or immunization. An improved understanding of host-pathogen interactions will drive forward the development of vaccines. This Special Issue of *Vaccines* will focus on detailing the implications of host-pathogen interactions or host-vaccine interactions on vaccine design, importantly, addressing the implications of host-pathogen or host-vaccine interactions for the identification of correlates of protection induced by vaccination.

Guest Editor

Dr. Randy A. Albrecht

Department of Microbiology, Global Health and Emerging Pathogens
Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Deadline for manuscript submissions

closed (31 October 2018)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/16621

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).